Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder
The use of individual glucagon-like peptide-1 receptor (GLP-1) agonists was compared with nonuse of GLP-1 agonists. Groupwise and use of specific AUD medications were compared with nonuse of AUD medications. Both of these models (A and B) were adjusted for time-varying use of psychotropic medications (antipsychotics, N05A; antidepressants, N06A; mood stabilizers, including carbamazepine, N03AF01; valproic acid, N03AG01; lamotrigine, N03AX09; and lithium, N05AN01), benzodiazepines and related drugs (N05BA, N05CD, N05CF), and attention-deficit/hyperactivity disorder (ADHD) medications (N06BA); use of antidiabetic drugs other than GLP-1 agonists (A10 excluding A10BJ); temporal order of GLP-1 medication; and time since cohort entry. aHR indicates adjusted hazard ratio.
The use of individual glucagon-like peptide-1 receptor (GLP-1) agonists was compared with nonuse of GLP-1 agonists. Groupwise and use of specific alcohol use disorder (AUD) medications were compared with nonuse of AUD medications. Both of these models (A and B) were adjusted for time-varying use of psychotropic medications (antipsychotics, N05A; antidepressants, N06A; mood stabilizers, including carbamazepine, N03AF01; valproic acid, N03AG01; lamotrigine, N03AX09; and lithium, N05AN01), benzodiazepines and related drugs (N05BA, N05CD, N05CF), and attention-deficit/hyperactivity disorder medications (N06BA); use of antidiabetic drugs other than GLP-1 agonists (A10 excluding A10BJ); temporal order of GLP-1 medication; and time since cohort entry. aHR indicates adjusted hazard ratio.
